Anti-GPRC5D CAR-T Cells Therapy (Shanghai YaKe Biotechnology)

GPRC5D CAR-T细胞治疗 (上海雅科生物)

Report date: 2024/07/29 16:14:53

Base Information

Drug NameAnti-GPRC5D CAR-T Cells Therapy (Shanghai YaKe Biotechnology)
Drug Alias NameGPRC5D targeted CAR T cell therapy (Yake Biotechnology)DeepTag-GPRC5D Targeted CAR T-cell therapyGPRC5D Targeted CAR T-cell therapy
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-GPRC5D
TargetsG-protein coupled receptor family C group 5member D
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai YaKe Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai YaKe Biotechnology Co LtdThe Affiliated Hospital Of Xuzhou Medical University
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A